GlassScriptPhysician profile
Andy F Williamson
NPI 1558354506
$9,073.33
in general payments reported to CMS, 2019-2025
57 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $691 · 2021: $1,341 · 2022: $1,261 · 2023: $1,414 · 2024: $1,607 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,329.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,413.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,018.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $702.34 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $553.20 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $495.16 | 2019-2025 | Veozah |
| Pfizer INC. | $419.52 | 2019-2025 | |
| Novo Nordisk INC | $414.18 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $385.93 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $359.49 | 2019-2021 | |
| Amgen INC. | $277.43 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $257.48 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $219.57 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $154.73 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $153.76 | 2019-2025 | Zepbound, Emgality, Reyvow |
| Noven Therapeutics, LLC | $132.41 | 2024-2025 | Xelstrym |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.